Major Ingredients

Each Capsule Contains Hydroxyurea USP 500mg.

Major Functionality

Significant tumour response to Hydroxyurea has been demonstrated in melanoma, resistant chronic myeloid leukaemia and recurrent metastatic or inoperable carcinoma of the ovary. Hydroxyurea used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip and carcinoma of the cervix. Hydroxyurea used in the management of β thalassemia, essential thrombocythemia and polycythemia vera. Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with recurrent moderate to severe painful crises.

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.